Investor Relations

EyePoint Pharmaceuticals, Inc. (Nasdaq:EYPT) is a pharmaceutical company committed to developing and commercializing innovative therapeutics to help improve the lives of patients with serious eye disorders. The Company’s pipeline leverages its proprietary Durasert® technology for extended intraocular drug delivery including EYP-1901, a potential twice-yearly sustained-delivery intravitreal anti-VEGF treatment initially targeting wet age-related macular degeneration. The Company has two commercial products: YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg, for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU® (dexamethasone intraocular suspension) 9%, for the treatment of postoperative inflammation following ocular surgery. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts.

Recent Releases

August 2, 2021
EyePoint Pharmaceuticals Announces Renowned Scientists to Join New Executive Scientific Advisory Board

Learn More

July 20, 2021
EyePoint Pharmaceuticals Receives Preliminary Extension to Pass-Through Payment Status for DEXYCU®

Learn More

July 6, 2021
EyePoint Pharmaceuticals Reports Positive 30-day Safety Results for all Cohorts from the DAVIO Trial of EYP-1901 for wet-AMD

Learn More

July 1, 2021 EyePoint Pharmaceuticals Announces New Category III CPT Code for DEXYCU® Intraocular Suspension, Approved by the American Medical Association Learn More

June 28, 2021
EyePoint Pharmaceuticals Joins Russell 2000® and Russell 3000® Index

Learn More

Events & Presentations

Building value through innovation, dedicated to making a difference.

IR CONTACTS
Stern Investor Relations
p. 212.362.1200
e. eyepoint@sternir.com

MEDIA RELATIONS CONTACT
Caren Begun
p. 973.263.8585
e. caren@greenroompr.com